Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation

17 Sept 2022

Abstract excerpt

Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have better clinical outcomes compared to those with residual disease (RD). Therefore, robust biomarkers that can predict pCR may help with triage and resource prioritization in patients with TNBC. Herein, we identified a gene panel predictive of RD and pCR in TNBC from the discovery (n = 90) treatment-naive tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Genomics and Diagnostics
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36142814
DOI: 10.3390/ijms231810901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationPMID 36142814Read ↗

Secondary Transcriptomic Analysis of Triple Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific BiomarkersSemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancerSemantic proximity Read ↗

Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxelSemantic proximity Read ↗

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseSemantic proximity Read ↗

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.Semantic proximity Read ↗

Decoding molecular signatures and identifying therapeutic targets in triple-negative breast cancer subtypes using omics and network analysis.Semantic proximity Read ↗

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Classification of triple-negative breast cancers based on Immunogenomic profilingSemantic proximity Read ↗

A Novel Immune Checkpoint-Related Gene Signature to Predict Overall Survival and Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.